|Bid||23.00 x 2200|
|Ask||27.99 x 800|
|Day's Range||26.72 - 27.59|
|52 Week Range||20.83 - 39.68|
|Beta (3Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.75|
NEW YORK , May 17, 2019 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the May 15 th and 16 th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available ...
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15th and 16th, 2019
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
Biotech company Hutchison China MediTech, known as Chi-Med, has filed for a Hong Kong listing, which four sources close to the matter said could raise up to $500 million. Chi-Med, which is already listed on the London Stock Exchange and the Nasdaq in New York, filed its listing application with the Hong Kong stock exchange on Monday. "We are delighted to announce our proposed Hong Kong listing and global offering of shares," said Simon To, Chairman of Chi-Med, which is 60.2 percent owned by CK Hutchison.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH.
LONDON, March 29, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib.
LONDON, March 28, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the.
LONDON, March 11, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and.
LONDON, Feb. 12, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study.
LONDON, Feb. 08, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March.
LONDON, Jan. 07, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th.
– Global SAVANNAH study of savolitinib / Tagrisso® combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showed MET-amplification among themost frequent.
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – –.
Nov 29 (Reuters) - Innovent Biologics Inc: * HAS ENTERED INTO A GLOBAL COLLABORATION AGREEMENT WITH HUTCHISON CHINA MEDITECH LIMITED * UNDER AGREEMENT, UNIT INNOVENT SUZHOU AND HUTCHISON MEDIPHARMA TO ...
LONDON, Nov. 29, 2018 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and.
LONDON, Nov. 26, 2018 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the.
– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 -- Hutchison China MediTech Limited.
Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine. The London-listed company - which is known as Chi-Med and is collaborating with Eli Lilly on the drug - said on Wednesday that the National Medical Products Administration of China had approved Elunate or fruquintinib in colorectal cancer. It is one of the first modern medicines discovered and developed in China, and the speedy green light from Chinese authorities is further evidence of the country's progress in speeding up drug approvals.
Hutchison China Meditech CEO Christian Hogg discusses the importance of capitalizing on opportunities and shares his outlook for biotech. (Source: Bloomberg)
NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Hutchison China MediTech Limited Sponsored ADR (NASDAQ: HCM ) will be discussing their earnings results in their H1 Earnings Call to be held on July 27, 2018 ...